Doki Tomoko, Mello Michael, Mock Dennis, Evans Jacqueline M, Kearns-Jonker Mary
Department of Cardiothoracic Surgery Research, Transplantation Biology Research Laboratory, Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
BMC Immunol. 2008 Feb 11;9:5. doi: 10.1186/1471-2172-9-5.
Xenotransplantation holds the promise of providing an unlimited supply of donor organs for terminal patients with organ failure. Pre-existing natural antibodies to the Galalpha1,3Galbeta1,4GlcNac-R (alphaGal) carbohydrate xenoantigen, however, bind rapidly to the graft endothelium and initiate hyperacute rejection of wild type pig grafts in humans. Experimental procedures designed to prevent xenoantibody-mediated rejection have been tested in gal knockout mice. These mice produce anti-gal xenoantibodies and are widely used as small animal models for xenotransplantation research. In this model, chimerism for cells expressing the gal carbohydrate can be achieved by transplantation of mixed cells or by transduction of bone marrow cells with viral vectors expressing a functional alpha1,3 galactosyltransferase gene. Chimerism induces tolerance to heart grafts expressing alphaGal. The mechanisms by which tolerance is achieved include systemic changes such as clonal deletion and/or anergy. Intragraft changes that occur during the early stages of tolerance induction have not been characterized.
Cytoprotective genes heme oxygenase-1 (HO-1), Bcl2, and A20 that have been reported to contribute to long-term graft survival in various models of accommodation were not expressed at high levels in tolerant heart grafts. Intragraft gene expression at both early (Day 10) and late (>2 month) time points after heart transplant were examined by real-time PCR and microarray analysis was used to identify changes associated with the induction of tolerance. Intragraft gene expression profiling using microarray analysis demonstrated that genes identified in the functional categories of stress and immunity and signal transduction were significantly up-regulated in early tolerant grafts compared with syngeneic control grafts. Biological process classification showed lower binomial p-values in the categories of "response to biotic stimulus, defense response, and immune response" suggesting that up-regulated genes identified in these grafts promote survival in the presence of an immune response. The expression of the incompatible carbohydrate antigen (alphaGal) was reduced by 2 months post-transplant when compared with the expression of this gene at Day 10 post-transplant. These results suggest that the gal carbohydrate antigen is downmodulated over time in grafts that demonstrate tolerance.
Our study suggests that tolerance is associated with intragraft gene expression changes that render the heart resistant to immune-mediated rejection. Genes associated with stress and immunity are up-regulated, however cytoprotective genes HO-1, Bcl2 and A20 were not up-regulated. The expression of the gal carbohydrate, the key target initiating an immune response in this model, is down-regulated in the post-transplant period.
异种移植有望为终末期器官衰竭患者提供无限的供体器官。然而,针对半乳糖α1,3-半乳糖β1,4-乙酰葡糖胺-R(αGal)碳水化合物异种抗原的预先存在的天然抗体,会迅速与移植器官的内皮细胞结合,并引发人类对野生型猪移植器官的超急性排斥反应。旨在预防异种抗体介导的排斥反应的实验程序已在α1,3-半乳糖基转移酶基因敲除小鼠中进行了测试。这些小鼠会产生抗αGal异种抗体,被广泛用作异种移植研究的小动物模型。在该模型中,通过混合细胞移植或用表达功能性α1,3-半乳糖基转移酶基因的病毒载体转导骨髓细胞,可以实现表达半乳糖碳水化合物细胞的嵌合现象。嵌合现象可诱导对表达αGal的心脏移植产生耐受性。实现耐受性的机制包括全身性变化,如克隆清除和/或无反应性。在耐受性诱导早期发生的移植器官内变化尚未得到明确描述。
据报道,在各种适应性模型中有助于移植器官长期存活的细胞保护基因血红素加氧酶-1(HO-1)、Bcl2和A20,在耐受性心脏移植中并未高水平表达。通过实时PCR检测心脏移植后早期(第10天)和晚期(>2个月)的移植器官内基因表达,并使用微阵列分析来识别与耐受性诱导相关的变化。使用微阵列分析进行的移植器官内基因表达谱分析表明,与同基因对照移植相比,在早期耐受性移植中,在应激、免疫和信号转导功能类别中鉴定出的基因显著上调。生物学过程分类显示,在“对生物刺激的反应、防御反应和免疫反应”类别中,二项式p值较低,这表明在这些移植中鉴定出的上调基因在存在免疫反应的情况下促进存活。与移植后第10天该基因的表达相比,移植后2个月时不相容碳水化合物抗原(αGal)的表达降低。这些结果表明,在表现出耐受性的移植器官中,半乳糖碳水化合物抗原随时间下调。
我们的研究表明,耐受性与移植器官内基因表达变化有关,这些变化使心脏对免疫介导的排斥具有抗性。与应激和免疫相关的基因上调,然而细胞保护基因HO-1、Bcl2和A20并未上调。在该模型中引发免疫反应的关键靶点半乳糖碳水化合物的表达在移植后阶段下调。